These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21262015)

  • 1. [New drugs: money-back guarantee?].
    Steenhoek A; Koopmanschap MA; Franken MG; Rutten FF
    Ned Tijdschr Geneeskd; 2011; 155():A2042. PubMed ID: 21262015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical researchers and pharmaceutical industry. Dangerous liaisons].
    Roos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(32):1668-71. PubMed ID: 10494304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of the medical value of a drug. A necessity for the Transparency Commission].
    Avouac B
    Therapie; 1992; 47(1):9-16. PubMed ID: 1523604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in bringing new drugs to the market.
    Ammann AJ
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329171
    [No Abstract]   [Full Text] [Related]  

  • 9. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 11. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing.
    Godman B; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Feb; 11(1):79-82. PubMed ID: 23322546
    [No Abstract]   [Full Text] [Related]  

  • 15. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of developing imaging agents for routine clinical use.
    Nunn AD
    Invest Radiol; 2006 Mar; 41(3):206-12. PubMed ID: 16481902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could conditional release of new drugs provide the information required to study drug effectiveness? - A discussion paper.
    Rawson NS; West R; Appel WC
    Can J Clin Pharmacol; 2000; 7(4):185-90. PubMed ID: 11118964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a pharmaceutical risk-sharing agreement when patients are screened for the probability of success.
    Mahjoub R; Ødegaard F; Zaric GS
    Health Econ; 2018 Jan; 27(1):e15-e25. PubMed ID: 28627808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug policy 1996].
    Bogaert M
    Verh K Acad Geneeskd Belg; 1997; 59(4):227-36. PubMed ID: 9490919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Out of sight. Pharmaceutical industry temporarily replaces hospitals as target.
    McLaughlin N
    Mod Healthc; 2004 Oct; 34(42):26. PubMed ID: 15552190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.